High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

Prostate cancer is the second-leading cause of death among American men, killing one in 44. In the United States, 3.3 million men are survivors of prostate cancer, and the risk for developing the ...

Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...

Biparametric MRI, which omits the dynamic contrast enhancement sequence, can detect clinically significant prostate cancer as well as multiparametric MRI. Biparametric MRI performs as well as ...

Targeting men in the top 10% of genetic risk helped detect high-grade prostate cancer that conventional screening would miss, paving the way for more personalized and effective early detection ...

Through GE Healthcare's AI Innovation Lab, Mass General Brigham and UW-Madison will pair the company's magnetic resonance imaging foundational model with real data from their hospital systems and then ...

About The Study: In men with suspected prostate cancer, provided image quality is adequate, an abbreviated biparametric magnetic resonance imaging (MRI) scan, with or without targeted biopsy, could ...

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

Treatments for localised prostate cancer have long been aimed at treating the whole prostate, either by surgical removal or by radiotherapy. However ...